Evaluation of a potential clinical interaction between ceftriaxone and calcium

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1534-1540

  Steadman, Emily ^a   Raisch, Dennis W ^b,c   Bennett, Charles L ^d,e   Esterly, John S ^a,f   Becker, Tischa ^c   Postelnick, Michael ^f   McKoy, June M ^e   Trifilio, Steve ^f   Yarnold, Paul R ^e   Scheetz, Marc H ^a,f  

^a MIDWESTERN UNIVERSITY   (United States)

^b University of New Mexico   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CEFTAZIDIME; CEFTRIAXONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DATA BASE; DRUG ANTAGONISM; DRUG SURVEILLANCE PROGRAM; EMBOLISM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRECIPITATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CALCIUM; CEFTRIAXONE; CHEMICAL PRECIPITATION; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG TOXICITY; EMBOLISM; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 77950102610     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01111-09     Document Type: Article

References (32)

1. Agence Française de Sécurité Sanitaire des Produits de Santé. 2006. Commission Nationale De Pharmacovigilance. Compte rendu de la réunion du mardi 31 Janvier 2006. http://www.afssaps. fr/var/afssaps-site/storage/original /application/ 9a61d1bc834c126780061cd16e2fba91.pdf. Accessed 23 May 2009.
2. Anonymous. 2008. Second meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. http://www.who.int/ selection-medicines/committees/subcommittee/2/Ceftriaxone.pdf. Accessed 23 August 2008.
3. Anonymous. 1970. Blood volume, p. 555. In K. Diem and C. Lentner (ed.), Scientific tables, 7th ed. J. R. Geigy S.A., Basel, Switzerland.
4. Avci, Z., A. Koktener, N. Uras, F. Catal, A. Karadag, O. Tekin, H. Degirmencioglu, and E. Baskin. 2004. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch. Dis. Child. 89:1069-1072.
5. Bennett, C. L., J. R. Nebeker, P. R. Yarnold, C. C. Tigue, D. A. Dorr, J. M. McKoy, B. J. Edwards, J. F. Hurdle, D. P. West, D. T. Lau, C. Angelotta, S. A. Weitzman, S. M. Belknap, B. Djulbegovic, M. S. Tallman, T. M. Kuzel, A. B. Benson, A. Evens, S. M. Trifilio, D. M. Courtney, and D. W. Raisch. 2007. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch. Intern. Med. 167:1041-1049.
6. Bickford, C. L., and A. P. Spencer. 2005. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy 25:1389-1395.
7. Bonapace, C. R., S. Fowler, K. A. Laessig, J. A. Lazor, and S. Nambiar. 2009. Ceftriaxone and calcium-containing fluids-rationale for product label changes, abstr. A1-008. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
8. Bradley, J. S., R. T. Wassel, L. Lee, and S. Nambiar. 2009. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 123:e609-e613.
9. European Medicines Agency. 2009. Pharmacovigilance working party monthly report. September. http://www.emea.europa.eu/pdfs/human/phvwp/ 59945009en.pdf. Accessed 29 December 2009.
10. Gin, A. S., H. Wheaton, and B. Dalton. 2008. Clinical pharmaceutics and calcium-ceftriaxone. Ann. Pharmacother. 42:450-451.
11. Grasberger, H., B. Otto, and K. Loeschke. 2000. Ceftriaxone-associated nephrolithiasis. Ann. Pharmacother. 34:1076-1077.
12. Infectious Diseases Society of America. 2004. Practice guidelines for the management of bacterial meningitis. http://www.journals.uchicago.edu/ doi/pdf/10.1086/425368. Accessed 23 August 2008.
13. Infectious Diseases Society of America/American Thoracic Society. 2007. Consensus guidelines on the management of community-acquired pneumonia in adults. http://www.journals.uchicago.edu/doi/pdf/10.1086/511159. Accessed 23 August 2008.
14. Kim, Y. S., M. F. Kestell, and S. P. Lee. 1992. Gall-bladder sludge: lessons from ceftriaxone. J. Gastroenterol. Hepatol. 7:618-621.
15. Lamb, H. M., D. Ormrod, L. J. Scott, and D. P. Figgitt. 2002. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs 62:1041-1089.
16. Lexi-Comp. 2009. Calcium gluconate monograph. http://online.lexi. com/crlsql/servlet/crlonline. Accessed 16 March 2009.
17. McCracken, G. H., Jr., J. D. Siegel, N. Threlkeld, and M. Thomas. 1983. Ceftriaxone pharmacokinetics in newborn infants. Antimicrob. Agents Chemother. 23:341-343.
18. Monte, S. V., W. A. Prescott, K. K. Johnson, L. Kuhman, and J. A. Paladino. 2008. Safety of ceftriaxone sodium at extremes of age. Expert Opin. Drug Saf. 7:515-523.
19. National Cancer Institute. 2009. Cancer therapy program evaluation: common terminology criteria for adverse events v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed 17 March 2009.
20. National Center for Health Statistics. 2000. CDC growth charts: United States. http://cdc.gov/growthcharts. Accessed 14 August 2008.
21. Nebeker, J. R., P. Barach, and M. H. Samore. 2004. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann. Intern. Med. 140:795-801.
22. Puzovic, M., and G. Hardy. 2008. Comment: clinical pharmaceutics and calcium ceftriaxone. Ann. Pharmacother. 42:1914.
23. Rapp, R. P., and R. Kuhn. 2007. Clinical pharmaceutics and calcium ceftriaxone. Ann. Pharmacother. 41:2072.
24. Roche Pharmaceuticals. 2009. Rocephin. Package insert. http://www.rocheusa.com/products/rocephin/pi.pdf. Accessed 16 April 2009.
25. Schaad, U. B., W. L. Hayton, and K. Stoeckel. 1985. Single-dose ceftriaxone kinetics in the newborn. Clin. Pharmacol. Ther. 37:522-528.
26. Schaad, U. B., and K. Stoeckel. 1982. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob. Agents Chemother. 21:248-253.
27. Shiffman, M. L., F. B. Keith, and E. W. Moore. 1990. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 99:1772-1778.
28. U.S. Food and Drug Administration. 2009. Information for healthcare professionals: ceftriaxone (marketed at Rocephin and generics). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm. Accessed 16 April 2009.
29. Wolters Kluwer Health. 2008. Ceftriaxone monograph. Facts and comparisons 4.0. Wolters Kluwer Health, St. Louis, MO. http://online. factsandcomparisons.com/MonoDisp.aspx?monoID=fandc-hcp10432&inProdGen= true&quick=Ceftriaxone. Accessed 23 August 2008.
30. Xia, Y., K. J. Lambert, C. D. Schteingart, J. J. Gu, and A. F. Hofmann. 1990. Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology 99:454-465.
31. Yarnold, P. R. 1996. Discriminating geriatric and non-geriatric patients using functional status information: an example of classification tree analysis via UniODA. Educ. Psychol. Meas. 56:656-667.
32. Yarnold, P. R., and R. C. Soltysik. 2005. Optimal data analysis. APA Books, Washington, DC.